Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.
Appears in 30 contracts
Sources: At the Market Issuance Sales Agreement (Airgain Inc), At the Market Issuance Sales Agreement (Airgain Inc), At the Market Issuance Sales Agreement (Microvision, Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the CommissionSEC, there shall will not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.
Appears in 30 contracts
Sources: At the Market Issuance Sales Agreement (ENDRA Life Sciences Inc.), At the Market Issuance Sales Agreement (Auddia Inc.), At the Market Issuance Sales Agreement (bioAffinity Technologies, Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.
Appears in 19 contracts
Sources: Capital on Demand Sales Agreement (Cassava Sciences Inc), At Market Issuance Sales Agreement (Aeterna Zentaris Inc.), At Market Issuance Sales Agreement (Aeterna Zentaris Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Change or any development in the business or affairs of the Company that could reasonably be expected to cause result in a Material Adverse EffectChange.
Appears in 15 contracts
Sources: Sales Agreement (Glimpse Group, Inc.), Sales Agreement (Spyre Therapeutics, Inc.), Sales Agreement (Dianthus Therapeutics, Inc. /DE/)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the CommissionSEC, there shall will not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could would reasonably be expected to cause a Material Adverse Effect.
Appears in 10 contracts
Sources: At the Market Issuance Sales Agreement (HiTek Global Inc.), At the Market Issuance Sales Agreement (Expion360 Inc.), At the Market Issuance Sales Agreement (Inno Holdings Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could would reasonably be expected to cause a Material Adverse Effect.
Appears in 7 contracts
Sources: At the Market Issuance Sales Agreement (Emerald Oil, Inc.), At the Market Issuance Sales Agreement (Emerald Oil, Inc.), At Market Issuance Sales Agreement (Echo Therapeutics, Inc.)
Material Changes. Except as contemplated in the Registration Statement and the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.
Appears in 7 contracts
Sources: At the Market Issuance Sales Agreement (Houston American Energy Corp), At the Market Issuance Sales Agreement (Soluna Holdings, Inc), At the Market Issuance Sales Agreement (Houston American Energy Corp)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the CommissionCommission and incorporated by reference in the Prospectus, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any or any Material Adverse Effect, Effect or any development in the business or affairs of the Company that could reasonably be expected to cause result in a Material Adverse Effect.
Appears in 7 contracts
Sources: Sales Agreement (AGNC Investment Corp.), Sales Agreement (MTGE Investment Corp.), Sales Agreement (MTGE Investment Corp.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development in the business or affairs of the Company that could reasonably be expected to cause result in a Material Adverse Effect.
Appears in 5 contracts
Sources: Sales Agreement (Revance Therapeutics, Inc.), Sales Agreement (Revance Therapeutics, Inc.), Sales Agreement (Proteostasis Therapeutics, Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could would reasonably be expected to cause a Material Adverse Effect.
Appears in 3 contracts
Sources: At Market Issuance Sales Agreement (Fortress Biotech, Inc.), At Market Issuance Sales Agreement (Coronado Biosciences Inc), At Market Issuance Sales Agreement (Coronado Biosciences Inc)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Change or any development in the business or affairs of the Company that could would reasonably be expected to cause result in a Material Adverse EffectChange.
Appears in 3 contracts
Sources: Sales Agreement (Revolution Medicines, Inc.), Sales Agreement (Savara Inc), Sales Agreement (Oncothyreon Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.
Appears in 3 contracts
Sources: At Market Issuance Sales Agreement (Geron Corp), At Market Issuance Sales Agreement (Geron Corp), At Market Issuance Sales Agreement (Geron Corp)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the CommissionCommission and incorporated by reference in the Prospectus, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development in the business or affairs of the Company that could reasonably be expected to cause result in a Material Adverse Effect.
Appears in 3 contracts
Sources: Sales Agreement (AGNC Investment Corp.), Sales Agreement (AGNC Investment Corp.), Sales Agreement (AGNC Investment Corp.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s 's reports filed with the CommissionCommission and incorporated by reference in the Prospectus, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any or any Material Adverse Effect, Effect or any development in the business or affairs of the Company that could reasonably be expected to cause result in a Material Adverse Effect.
Appears in 2 contracts
Sources: Sales Agreement (American Capital Agency Corp), Sales Agreement (American Capital Agency Corp)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect..
Appears in 2 contracts
Sources: Sales Agreement (Cassava Sciences Inc), Capital on Demand Sales Agreement (Pain Therapeutics Inc)
Material Changes. Except as contemplated in the ProspectusProspectuses, or disclosed in the Company’s 's reports filed with the CommissionCommission or Canadian Qualifying Authorities, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Change or any development in the business or affairs of the Company that could reasonably be expected to cause result in a Material Adverse EffectChange.
Appears in 2 contracts
Sources: Equity Distribution Agreement (High Tide Inc.), Equity Distribution Agreement (High Tide Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, Change or any development in the business or affairs of the Company that could reasonably be expected to cause result in a Material Adverse EffectChange.
Appears in 2 contracts
Sources: Sales Agreement (TSR Inc), Sales Agreement (TSR Inc)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse changeMaterial Adverse Change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Change or any development in the business or affairs of the Company that could would reasonably be expected to cause result in a Material Adverse EffectChange.
Appears in 2 contracts
Sources: Sales Agreement (Revolution Medicines, Inc.), Sales Agreement (Revolution Medicines, Inc.)
Material Changes. Except as contemplated in the Prospectus, Prospectus or disclosed in the Company’s reports filed with the CommissionSEC, there shall will not have been any material adverse change, on a consolidated basis, in the authorized share capital stock of the Company or any Material Adverse Effect, Effect or any development in the business or affairs of the Company that could would reasonably be expected to cause a Material Adverse Effect.
Appears in 2 contracts
Sources: At the Market Issuance Sales Agreement (Haoxi Health Technology LTD), At the Market Issuance Sales Agreement (Innovation Beverage Group LTD)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could would reasonably be expected to cause a Material Adverse Effect., that in each case, is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus
Appears in 1 contract
Sources: At the Market Issuance Sales Agreement (Kalobios Pharmaceuticals Inc)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development in the business or affairs of the Company that could reasonably be expected to would cause a Company Material Adverse Effect.
Appears in 1 contract
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse changeMaterial Adverse Change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse EffectChange, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.a
Appears in 1 contract
Sources: Sales Agreement (BGC Partners, Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the CommissionSEC, there shall will not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could would reasonably be expected to cause a Material Adverse Effect.
Appears in 1 contract
Sources: At the Market Issuance Sales Agreement (Medigus Ltd.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.,
Appears in 1 contract
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the CommissionSEC, there shall will not have been any material adverse change, on a consolidated basis, in the authorized share capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could would reasonably be expected to cause a Material Adverse Effect.
Appears in 1 contract
Sources: At the Market Issuance Sales Agreement (SciSparc Ltd.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s 's reports filed with the CommissionSEC, there shall will not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could would reasonably be expected to cause a Material Adverse Effect.
Appears in 1 contract
Sources: At the Market Issuance Sales Agreement (Flora Growth Corp.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.
Appears in 1 contract
Sources: Sales Agreement (Cerus Corp)
Material Changes. Except as contemplated in the Prospectus, Registration Statement or disclosed in the Company’s reports filed with the CommissionSEC and incorporated by reference into the Registration Statement, there shall has not have been any material adverse change, on a consolidated basis, change in the Company’s authorized capital stock of the Company or any Material Adverse Effect, Effect or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse EffectEffect on the Company.
Appears in 1 contract
Material Changes. Except as contemplated in the U.S. Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.
Appears in 1 contract
Sources: At Market Issuance Sales Agreement (Aeterna Zentaris Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s 's reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.
Appears in 1 contract
Sources: At the Market Issuance Sales Agreement (Microvision, Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the CompanyCompany and Parent’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company and the Parent or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.
Appears in 1 contract
Sources: At the Market Issuance Sales Agreement (Gastar Exploration USA, Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development in the business or affairs of the Company that could would reasonably be expected to cause result in a Material Adverse Effect.
Appears in 1 contract
Material Changes. Except as contemplated in the U.S. Prospectus, or disclosed in the Company’s 's reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.
Appears in 1 contract
Sources: At Market Issuance Sales Agreement (Aeterna Zentaris Inc.)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development in the business or affairs of the Company that could would reasonably be expected to cause result in a Material Adverse Effect.. US-DOCS\111349286.7
Appears in 1 contract
Sources: Common Stock Sales Agreement (Allogene Therapeutics, Inc.)